Savient Pharmaceuticals, Inc. (SVNT) Submits New Drug Application For Soltamox To The U.S. FDA 
10/19/2005 5:11:56 PM

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Jan. 6, 2005--Savient Pharmaceuticals, Inc. (NASDAQ: SVNT), an emerging specialty pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that address unmet medical needs is pleased to announce the submission of a New Drug Application ("NDA") with the U.S. Food and Drug Administration ("FDA") of Soltamox(R) (tamoxifen oral liquid solution) for the treatment of hormonally sensitive breast cancer. Soltamox is the product of Savient's wholly-owned subsidiary, Rosemont Pharmaceuticals Ltd. located in Leeds, U.K.